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1. BACKGROUND. THE ISPOR TASK FORCE PROCESS 16 
ISPOR to insert details here 17 
2. INTRODUCTION  18 
The assessment of health-related quality of life is critical in the evaluation of health care 19 
WHFKQRORJLHVDQGVHUYLFHVDQGLQUHJXODWRU\DQGUHLPEXUVHPHQWGHFLVLRQV³3UHIHUHQFH-based 20 
PHDVXUHV´3%0VSOD\DFHQWUDOUROHLQWKHVHHYDOXDWLRQV. They allow patients to describe 21 
the impact of ill health and have an associated ³XWLOLW\´VFRUH (or tariff) for each of those 22 
health state descriptions where a value of 1 represents full health, 0 represents the value of 23 
dead, and negative values (if defined by the PBM) represent states worse than death. These 24 
utility scores can then be used for the calculation of Quality Adjusted Life Years (QALYs), 25 
which are an outcome metric for health benefit used in many health economic evaluations. 26 
The most widely-used PBMs are generic: applicable to a wide range of diseases, patients and 27 
interventions. Examples include the EQ-5D1, SF-6D2, a derivative of the SF-36 instrument, 28 
and the Health Utilities Index (HUI)3. Many national guidelines for economic evaluation 29 
suggest or require the use of these generic instruments, such as England and Wales4 , Spain5, 30 
France6, Thailand, Finland, Sweden, Poland, New Zealand, Canada, Colombia and The 31 
Netherlands.  Some recommend the use of a particular instrument, usually the EQ-5D7.  32 
In many situations, clinical studies do not include a PBM. Often they will include one or 33 
more of the many patient-reported outcome measures (PROMs) which are not full PBMs 34 
because they do not have an associated, preference-based scoring system. Thus they do not 35 
permit construction of a QALY measure. Studies typically will also include physical 36 
outcomes (not patient-reported) which are PHDVXUHG ³REMHFWLYHO\´ WKDW LV, without the 37 
interpretation of or report by the patient. In the absence of a PBM outcome, researchers will 38 
need to derive the ³missing´ PBM in order to estimate QALYs from these studies.  In these 39 
circumstances the question is whether it is possible, and how, to predict the value that a PBM 40 
would have taken had this been collected, given what we know about the observed clinical 41 
outcome(s) and allowing for the mediating effect of the individual characteristics of study 42 
participants.  ³0DSSLQJ´attempts to answer this question and, in so doing, bridges the gap 43 
that often exists between available evidence on the effect of a health technology in one metric 44 
and the requirement for decision makers to express it in a different one (QALYs). It can also 45 
be used to provide a means of converting outcomes in one PBM to a different PBM. 46 
³0DSSLQJ´ PDNHV XVH RI DQRWKHU GDWDVHW which may be observational rather than 47 
experimental. This dataset must have the same outcomes that are measured in the relevant 48 
clinical study/studies, and the SDWLHQWV¶ UHVSRQVHV WR D VWDQGDUG 3%0 LQVWUXPHQW This 49 
external dataset is used to estimate a statistical relationship between the two types of outcome 50 
measure. Combining the estimated statistical relationship together with the outcome data 51 
from the trial allows an estimate of the effect of the treatment in health utility terms and 52 
subsequently may be used to calculate QALYs. The practice of fitting a statistical model to 53 
health utility data has variously been referred to DV µµPDSSLQJ¶¶ µµFURVV-walking¶¶ DQG54 
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µµWUDQVIHUWRXWLOLW\¶¶8. ³0DSSLQJ´KDVHQWHUHGLQWRFRPPRQXVDJHVRLVXVHG throughout this 55 
report.  56 
In the context of economic evaluation, the evidence gap which gives rise to the need for 57 
mapping is commonly encountered. For example, Kearns et al (2013)9 reviewed 79 recent 58 
NICE Technology Appraisals and found that mapping models were used in almost a quarter 59 
of cases. These included mapping from the Psoriasis Area Severity Index (PASI) in patients 60 
with psoriasis, from the Functional Assessment of Cancer Therapy ± General (FACT-G) in 61 
patients with cervical cancer, and from  the Patient Assessment of Constipation ± Symptoms 62 
(PAC-SYM) and Patient Assessment of Constipation ± Quality of Life (PAC-QOL) in 63 
women with chronic constipation, inter alia. The need for mapping may arise because of a 64 
failure to include a PBM in the relevant clinical studies (as described above), or because 65 
those studies are not sufficient alone to provide the utility information to estimate cost-66 
effectiveness. There could be a requirement for extrapolation beyond the range of health 67 
states observed in clinical studies or a requirement to synthesise evidence from several 68 
clinical studies, not all of which include evidence on PBMs. Thus, mapping is an issue both 69 
for economic evaluation alongside trial data analysis without PBMs as well as for many 70 
economic modelling studies. And because studies that have been conducted historically will 71 
remain part of the evidence base as comparators for the evaluation of new technologies, 72 
mapping is likely to remain a requirement for some time, even when good practices for utility 73 
estimation are followed in contemporary clinical studies10. 74 
The current practice of mapping includes substantial variation in methods which are known 75 
to lead to differences in cost-effectiveness estimates11,12. The purpose of this Task Force 76 
report is to set out Good Research Practices that are relevant for the conduct of mapping 77 
studies for use in all types of QALY-based economic evaluation. The recommendations also 78 
have broader relevance to all situations where analysts wish to estimate preference-based 79 
outcomes as a function of any other variables, for example, where utilities are used as 80 
measures of provider performance13. Recommendations cover all areas of mapping practice:  81 
the selection of datasets for the mapping estimation, model selection and performance 82 
assessment, reporting standards, and the use of results including the appropriate reflection of 83 
variability and uncertainty. Such recommendations are critical in the face of inconsistent 84 
current practices, substantial variation in results between approaches and the risk of bias in 85 
several methods. Whilst other recommendations have been made14,15, this document is unique 86 
because it takes an international perspective, is comprehensive in its coverage of the aspects 87 
of mapping practice, and reflects the current state of the art.   88 
 
3. PRE-MODELLING CONSIDERATIONS 89 
Prior to undertaking a statistical analysis for the purpose of mapping, the analyst must 90 
consider a number of different factors relating to the proposed and potential uses of the 91 
mapping itself. These uses create requirements for the dataset(s) in which the statistical 92 
analyses will be undertaken and tested. 93 
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Mapping is almost always undertaken with some pre-defined purpose and in many of those 94 
cases this is to inform a specific cost-effectiveness analysis (CEA).  Clear understanding of 95 
the evidence gap to be addressed requires an understanding of relevant existing utility 96 
evidence, the requirements of the decision-making body that will assess the results of the 97 
analysis and the CEA in which the results are to be used. These factors help to inform the 98 
analytical choices which ensure unbiased estimates in the cost-effectiveness study. There will 99 
be requirements to appropriately reflect uncertainty and, additionally in some situations, the 100 
variability of estimates (for example, if simulating individual patients in a cost-effectiveness 101 
model). 102 
7KHQHHGVRIWKH&($ZLOOKHOSJXLGHWKHDQDO\VW¶VFKRLFHRIPHWKRGVDQGGDWDVHWVWKDWFDQ103 
be expected to perform appropriately for these specific needs. Where the analysis is to be 104 
used to populate a decision analytic model, one needs to consider what health states are 105 
reflected in that model  ± how are they defined and how do those definitions relate to both the 106 
clinical outcome measure or measures of relevance and the target PBM? If there is little 107 
overlap between the clinical outcomes and the PBM then mapping is unlikely to be 108 
successful. A descriptive comparison of the content of the different outcome measures, 109 
including the suggested PBM, is a useful starting point. This will highlight the specific facets 110 
of health each instrument measures. It is not a requirement for the PBM and clinical 111 
outcomes to address the same symptoms or functional (dis)abilities in order for mapping to 112 
be an appropriate approach but they do need to measure the same underlying concepts.   113 
Many models, such as transition state models, will typically define a relatively small number 114 
of discrete health states. Other situations may require a combination of health states that can 115 
be derived in part from a mapping study and in part from other evidence. For example, the 116 
model may differentiate health states based on a disease outcome measure and the therapy 117 
patients are receiving, or the adverse events they experience, or their comorbidities. Mapping 118 
and other existing evidence can provide a range of options for addressing these evidence 119 
gaps.      120 
Mapping outcomes to the utilities of a PBM is usually done with regression analyses. At one 121 
end of the spectrum, there are rare occasions where regression models can be avoided entirely 122 
simply by taking the mean and variance of the utility value for patients with the relevant 123 
health criteria. This simple approach is entirely legitimate if there is a single summary 124 
measure of disease to explain utility with no additional covariates that are considered 125 
important and there are sufficient observations of patients within each category. However, it 126 
should be noted that this may limit the generalisability of the mapping to other CEAs where 127 
these conditions do not hold. 128 
Regression type analyses do become a requirement once additional covariate and/or 129 
extrapolation outside the range of the observed data are required, as is often the case. This 130 
might be because there are multiple disease specific outcome measures that reflect different 131 
dimensions of disease that collectively are used to estimate health utility. Or it could be 132 
because the analyst wishes to incorporate the effect of socio-demographics on health utility. 133 
For instance, age is likely to be a relevant variable in many situations as it will be related to 134 
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health and quality of life. Another reason to consider regression models for mapping is the 135 
possibility of the need to extrapolate beyond the range of disease severity observed in the 136 
data. Whilst extrapolation beyond the range of the data is best avoided in any situation, this is 137 
not always feasible. Mapping studies are frequently based on datasets that do not include the 138 
full range of patient disease severity, particularly when these datasets are from randomised 139 
controlled trials with exclusion criteria for comorbidities and other aspects of severity. This 140 
contrasts with the needs of decision models, particularly those for patients with chronic 141 
conditions, which may PRGHOSDWLHQWV¶OLIHWLPHVDQGWKXVspan the entire feasible spectrum of 142 
disease.  143 
It is well established that some methods for such regression analyses exhibit bias, the extent 144 
of which is in part dependent on the target utility measure.  More details are provided in 145 
section 4, but it can be noted at this point that bias is typically greatest at the extremes of 146 
disease severity ± for patients in severe ill- health these approaches overestimate their true 147 
health utility and for those in good health they underestimate health utility16. With this in 148 
mind the analyst must assess the requirements of the CEA. For instance, what is the range of 149 
disease to be addressed by the decision model?  This judgment should not only be made 150 
against the characteristics of candidate patients at the point in the patient pathway where the 151 
technology of interest is being assessed (model baseline), but should be informed by the 152 
range of future health states to be covered in the model.  Since this may cover a long term 153 
extrapolation encompassing patients experiencing diverse pathways including disease 154 
progression, therapy response and disease remission, a very wide range of disease severity 155 
can sometimes be covered. 156 
Similar considerations influence the requirements for datasets in which the mapping function 157 
is to be estimated. Additional requirements are that, obviously, candidate datasets must come 158 
from studies of individuals completing both the relevant clinical outcome measure(s) and the 159 
target PBM simultaneously. There is no reason why randomised studies would be more 160 
desirable for mapping studies. Indeed, as alluded to above, randomised studies often have less 161 
diverse patients than other study types in terms of disease severity because of strict inclusion 162 
and exclusion criteria and limited follow up. Observational studies may be more likely to be 163 
drawn from representative patient groups, have larger sample sizes and can be conducted at 164 
relatively low cost. Where there is more than one candidate dataset then consideration should 165 
be given to the additional data fields the different studies include which may facilitate more 166 
precise estimates of the target PBM as well as the sample size, generalisability of the patient 167 
population and any potential biases in the study designs. However, this needs to be balanced 168 
with the use of those values in subsequent CEAs. The availability of information on 169 
UHVSRQGHQWV¶DJH, for example, is likely to improve model fit and ought to be incorporated 170 
into a CEA. Datasets may be combined where common covariates exist and differences 171 
between patients and study designs are not expected to influence the relationship between 172 
covariates and PBM. 173 
Uncertainty in the estimates should be minimized. This is facilitated in part by the use of 174 
datasets with larger numbers of observations and by avoiding extrapolation beyond the range 175 
of the data when feasible. Matching the range of disease severity in the dataset with the 176 
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population of the CEA is important, but the range of other patient characteristics used as 177 
covariates in the mapping model are also relevant here. 178 
Finally, the analyst needs to be aware of any potential biases in the dataset. Biases in this 179 
situation refers to those factors ZKLFKLQIOXHQFHDSDWLHQW¶VUHSRUWHGKHDOWKXWLOLW\RWKHUWKDQ180 
through an impact on the clinical outcome measure(s) used as explanatory variables. For 181 
instance, in some situations the types of therapies patients are receiving may exert some bias, 182 
for example, where those therapies are associated with adverse events unrelated to the clinical 183 
outcome being measured in the mapping dataset.  184 
 185 
    
 
 
 
 
 
 
 
 
 
4. MODELLING AND DATA ANALYSIS 186 
Selection of the statistical model 187 
Utility measures tend to exhibit a number of non-normal distributional characteristics. These 188 
measures can be considered a type of limited dependent variable at both the top and bottom 189 
of their ranges: by definition a value of 1 is the maximum value that can be achieved and is 190 
FRQVLGHUHGHTXDOWR³IXOOKHDOWK´7KHUHLVDORZHUOLmit which varies by instrument, 191 
sometimes UHIHUUHGWRDVWKH³SLWV´VWDWH. Note that these limits in utilities are not the same as 192 
³FHQVRULQJ´ 193 
Additional aspects of the distribution of utilities that influence the statistical model choice are 194 
the presence of large spikes in the distribution (W\SLFDOO\DWWKH³IXOOKHDOWK´XSSHUERXQG), 195 
skewness, multimodality and gaps in the range of feasible values. Figure 1 displays examples 196 
of the distribution of EQ5D-3L from a range of different disease areas. The extent to which 197 
these features are present varies according to the instrument and scoring algorithm of the 198 
PBM that is the target for the mapping study, and the nature of the patient group. The 199 
presence of any of these features makes the application of simple statistical regression 200 
Summary of pre-modelling recommendations 
1. Consider the use or potential uses of the mapping: 
a. Is it for use in a cohort decision model, patient level model or trial-based cost- 
effectiveness analysis?  
b. What are the health states that require utility estimates from the mapping and how do 
they relate to the PBM? 
c. What is the range of disease severity for which utility values are required? 
2. Provide a descriptive account of the clinical explanatory variable, the dependent PBM and the 
extent to which they overlap. 
3. Assess if a regression-based mapping is required. 
a. How many health states require estimates of utility? 
b. Are there additional covariates of importance? 
c. Are there sufficient observations within each category?  
4. Identify if more than one dataset is potentially available for estimation. Compare the 
characteristics of candidate datasets. 
5. To what extent does the distribution of patient characteristics in the sample datasets reflect those 
that are the subject of the cost effectiveness analysis? In particular, are all extremes of disease 
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methods challenging and this is compounded when several of these features are 201 
simultaneously present.  202 
Figure 1. The distribution of EQ5D-3L across different disease areas 203 
 
There is considerable evidence that these distributional features result in systematic bias 204 
when linear regression methods are used to analyze the EQ-5D-3L instrument, the most 205 
commonly studied patient reported outcome in the mapping literature17,18,19. Similar findings 206 
have been shown to apply to models like the Tobit19 (designed to deal with limited dependent 207 
variables), two-part models20 (which attempt to address the mass of observations seen at full 208 
health) and censored least absolute deviations models21,22. A common finding in those reports 209 
is that expected health utility associated with mild health states is underestimated whilst 210 
 Asthma (n=2,935) 
 
0%
5%
10%
15%
20%
25%
30%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
Chest pain (n=679) 
 
0%
5%
10%
15%
20%
25%
30%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
Cronic obstructive pulmonary disease 
(n=185) 
0%
2%
4%
6%
8%
10%
12%
14%
16%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
 Clodronate (n=320) 
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
Hormone replacement therapy (n=755) 
0%
5%
10%
15%
20%
25%
30%
35%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
Irritable bowel syndrome (n=374) 
0%
5%
10%
15%
20%
25%
30%
35%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
 Lower back pain (n=500) 
0%
5%
10%
15%
20%
25%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
Leg Ulcers (n=233) 
0%
2%
4%
6%
8%
10%
12%
14%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
Leg reconstruction (n=92) 
0%
5%
10%
15%
20%
25%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
 Osteoporosis (n=221)  
0%
5%
10%
15%
20%
25%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
Varicose veins (n=887) 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
-
0.3
-
0.2
-
0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
EQ-5D score
Pr
o
po
rt
io
n
 
o
f R
es
po
n
de
n
ts
 
 
 
 8 
 
utility for more severe health states is overestimated. When mapping studies with these biases 211 
are used in economic evaluations, clinically effective therapies appear less cost-effective than 212 
they truly are. Studies have shown that the magnitude of this bias is not trivial11,12. 213 
Recent work compares the performance of different statistical methods for mapping. One set 214 
of methods estimate the summary utility score directly. Amongst these direct methods, there 215 
is some empirical evidence to support the performance of two approaches: the limited 216 
dependent variable mixture model approach19,12 and the beta-based regression approaches17,23.     217 
Alternatively, indirect methods estimate utilities as part of a two-stage procedure24. These 218 
methods have also demonstrated improvements over standard methods in some 219 
settings12,25,26,27. In the first stage, a so-FDOOHG³UHVSRQVHPDSSLQJ´PRGHOXVHVDVHULHVRI220 
(either dependent or independent) separate regression functions to estimate the level on each 221 
separate domain of the descriptive system of the target PBM. Models suitable for ordered 222 
categorical data should be used for this first stage and the correlation between dimension 223 
responses incorporated27 It is then straightforward to calculate the expected utility score as 224 
stage 2 of the procedure based on the probabilities assigned to each of the health states in the 225 
descriptive system and their associated utilities. This separation allows the analyst to apply 226 
any utility tariff to the models estimated in stage 1, according to their requirements. However, 227 
it should be noted that the appropriateness of the model and its fit is specific to the tariff in 228 
which it has been tested. Furthermore, response mapping models require sufficient 229 
observations in each of the levels of the descriptive system. Without this, the model(s) cannot 230 
be estimated.  231 
We do not advocate any specific set of methods as the performance of different methods will 232 
vary according to the characteristics of the target utility measure, the disease and patient 233 
population in question, the nature of the explanatory clinical variables and the form of 234 
intended use in the CEA. We therefore suggest that it is wise to use a model type for which 235 
there is existing empirical evidence of good performance, and that respects the key features 236 
of the target utility measure, particularly the limited range of feasible utility values that can 237 
be taken in order to avoid problems in implementing results in a cost-effectiveness model.  238 
Obviously, mapping does require analysts to adhere to good practice for statistical analysis in 239 
general. Below, we highlight some aspects of good practice that relate in particular to 240 
mapping.  For instance, a plot of the distribution of the target utility measure provides a 241 
starting point for considering potentially appropriate modelling methods for direct analysis of 242 
the utility index. Analysts should use models that have theoretical plausibility, whose key 243 
assumptions hold, and that have a body of existing empirical evidence supporting their 244 
validity in the mapping literature. The use of models that do not meet these criteria requires 245 
additional justification and the results should be subject to additional scrutiny. This additional 246 
justification can be in the form of evidence that demonstrates that the mapping does not 247 
suffer from bias in the particular application, or that the nature of that bias is not an issue 248 
given the use of the mapping in CEA. For example, if the analyst intends to populate a cohort 249 
decision model where only a small number of health states are defined and these health states 250 
are not located at the extremes of poor/good health, then bias from the mapping may have a 251 
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negligible effect on estimated cost-effectiveness. However, it is difficult to assess the impact 252 
of any potential bias a priori.  253 
In most situations it will be extremely important to utilize mapping methods that meet the 254 
criteria set out above. This is because the extent and impact of biased estimates on cost-255 
effectiveness will be significant and predictions outside the feasible utility range could be 256 
made.  For example,  model-based CEAs where health states  are at the extremes of disease 257 
severity, individual patient simulation models, or analyses based on individual level data such 258 
as CEAs conducted alongside a single clinical trial will all be at risk of substantially biased 259 
cost-effectiveness estimates if inappropriate mapping methods are applied.  260 
We note that some model types will require iterative estimation methods. It is imperative that 261 
the analyst ensures proper convergence of the estimation algorithm, whether undertaken in a 262 
classical28 or Bayesian29 framework. 263 
It is also typical for candidate datasets to comprise multiple observations from the same 264 
individuals over time. In general one should seek to make use of all observations. Multilevel 265 
models can be used to reflect the correlations between these observations. At a minimum, 266 
clustered standard errors should be calculated. Where there are reasons to believe that there 267 
has been a break in the relationship between the covariates and the PBM then separate 268 
models should be estimated and the stability of the parameters tested.  269 
The selection of covariates 270 
In most situations the dataset in which the mapping is to be performed will contain 271 
information on a range of potential explanatory variables. The primary decision for the 272 
analyst concerns the choice of non-preference-based measure that will serve as the key link 273 
between the clinical effectiveness data and the preference-based one. In many situations the 274 
non-preference-based measure will be obvious because it will be the primary outcome 275 
measure used in clinical studies, or the sole quality of life instrument amongst the secondary 276 
outcomes. However, often those measures are formed of individual questions, which in turn 277 
can be reported either as dimension scores or a single summary score. Typically, there will be 278 
greater explanatory power from a regression model that uses disaggregated information from 279 
an outcome measure as explanatory variables. However, not only does this increase the 280 
number of explanatory variables but it may not provide the link to clinical evidence in a form 281 
that is widely usable (see, for example, Longworth et al30 who modelled the 36 individual 282 
question responses to the EORTC instrument). This can be illustrated using the example of 283 
Rheumatoid Arthritis (RA). Typically, cost-effectiveness studies make use of the Health 284 
Assessment Questionnaire (HAQ) mapped to a preference-based instrument31. The HAQ is a 285 
summary score of functional impairment that ranges from 0-3 derived from 8 sub-sections 286 
each of which is comprised of 2 or 3 individual questions. Whilst the analyst may find a 287 
better performing model if using the individual item or dimension scores as explanatory 288 
variables, as opposed to the single 0-3 summary score, this should not be the sole criteria for 289 
covariate choice (see, for example, Bansback et al32). Where the mapping function is to be 290 
used to estimate health utility from individual questions or component scores, as might be the 291 
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case in an economic evaluation conducted alongside a clinical trial, such an approach will be 292 
useful. However, decision models that synthesize data from several clinical studies will 293 
typically rely on the published results which will report only the summary score.  294 
In other settings the analyst may have a choice of one or more disease specific outcomes. In 295 
Ankylosing Spondylitis (AS) for example, clinical studies typically report both BASDAI and 296 
BASFI outcomes measures of disease activity and functional impairment. The conceptual 297 
overlap with a preference-based instrument may be improved by the inclusion of multiple 298 
instruments and, hence, model fit.  299 
Covariates can also be sociodemographic, disease characteristics and treatments. It is good 300 
practice to include covariates in order to avoid mis-specification of the model (resulting in the 301 
effects of the omitted variable being allocated to the error term and biased estimates for the 302 
coefficients). This remains the case even though the economic evaluation may not be 303 
designed to directly use each of these explanatory variables. The analyst can still use the 304 
mapping and simply set the value of the explanatory variable to that appropriate to their 305 
setting. This is preferable to omitting the explanatory variable. Of course, judgment is 306 
required here in order to avoid the inclusion of covariates that are highly correlated in the 307 
interest of developing a parsimonious mapping model.  308 
Covariates should be theoretically justified a priori and reported in a manner that permits 309 
analysts to use results whether the covariate in question is used directly in their specific CEA 310 
or not. For instance, for most uses of mapping functions in CEA, the inclusion of age as a 311 
covariate is required and should be retained in preferred models even if not statistically 312 
significant.  This allows any effect of ageing, independent of that which is captured as part of 313 
the clinical outcome measure(s), to be properly reflected. Where the mapping is intended for 314 
use in a CEA alongside a trial, covariates common to both the mapping dataset and the trial 315 
can be used to improve the generalizability of one to the other.  316 
 317 
 
 
 
 
 
 
 
 
 
Summary of statistical modelling recommendations 
1. Consider whether the cost-effectiveness analysis requires a formal regression based mapping 
model approach, or if it is suitable to take the mean value for sub-samples of patients. 
2. If regression is required then model selection should be based on: 
a. Consideration of the most straightforward statistical model type whose assumptions are 
compatible with the target utility instrument. Use a plot of the distribution of the utility 
data to help inform that choice.  
b. Existing empirical evidence of the performance of different methods. There is no reason 
for this to be restricted to evidence from any specific disease area. 
c. The type of cost-effectiveness analysis where the mapping will be used and the extent to 
which biased estimates will affect the results. 
3. For response mapping, models should be selected that respect the ordered nature of the categorical 
data in the descriptive system. Expected values should be calculated analytically. 
4. Selection of the preferred mapping model is an iterative process that should conform to good 
practice common to all regression analyses.  
5. Covariates should be theoretically justified a priori. Exclusion of covariates, even if they are not 
to be used in the cost-effectiveness model, risks mis-specification.  
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5. REPORTING OF MAPPING STUDIES 318 
Mapping studies often form an important element of evidence submitted to decision-making 319 
Health Technology Assessment (HTA), pricing or reimbursement authorities. The findings 320 
must, therefore, be reported in a manner that allows a full assessment of the quality and 321 
relevance of the mapping by those that do not have access to the individual level data. In 322 
addition to this transparency requirement, it will be helpful to other analysts that sufficient 323 
information is reported to use the results in their own CEAs.  324 
The dataset 325 
Where more than one dataset could feasibly be used for mapping, provide a qualitative 326 
account of the selection rationale, at a minimum. The characteristics of the sample used in the 327 
estimation dataset must be provided fully. All variables should be described in terms of a 328 
measure of central tendency and distribution. Special attention should be given to the full 329 
distribution of patient observations at the extremes of disease severity, as described by the 330 
disease specific measures to be used as explanatory variables. This gives an indication of the 331 
extent to which the sample overlaps with the patients that are the focus of any CEA and, 332 
therefore, the extent of extrapolation required beyond the observed data.  333 
Full information must be provided about the methods for sampling patients, both in the study 334 
as a whole and those sub-samples selected for use in the mapping study. 335 
Many studies will include multiple observations from the same individuals over time. In this 336 
situation, it is important to report the pattern of those multiple, longitudinal observations and 337 
any features of the patients that change over those observations. For instance, if the follow-up 338 
period is substantial, then age is an important variable that will vary substantially from 339 
baseline. The number of available observations will differ according to the combination of 340 
covariates selected and this can lead to substantial differences between any final analysis and 341 
the description of the entire study sample. This also has implications for the ability to 342 
compare between models using measures of fit or penalised likelihood statistics.  343 
Justification of statistical model type 344 
As outlined above, there are numerous statistical challenges inherent in the analysis of utility 345 
data arising from its distributional features. The analyst should seek to select and justify their 346 
choice of method(s) a priori with reference to existing literature that has tested alternative 347 
methods using the target preference-based measure in question, examination of the 348 
distributional features in the estimation dataset, and the proposed use of the mapping function 349 
in any future cost-effectiveness study. 350 
An algebraic description of the model is transparent, concise, unambiguous and ensures 351 
results can be used correctly by any competent analyst. Non-standard models, that have not 352 
been described elsewhere, must always contain such a description. An example of a predicted 353 
value from the mapping regression for some set of covariates should be reported. In some 354 
publications, additional software that calculates predictions for user defined inputs has been 355 
provided25,33. 356 
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Justification for covariates used and how specified 357 
Datasets used for mapping will typically offer the analysts a broad range of potential 358 
explanatory variables. These cover disease specific outcome measures, which often may be 359 
scored either as multiple components or summary index scores, of which there may be more 360 
than one, clinical measures, symptom specific information and demographics inter alia. A 361 
theoretical justification should be given for the inclusion of all variables within the set to be 362 
examined in the statistical analyses. It is instructive to provide an account of the dimensions 363 
of quality of life covered in the disease specific outcome(s) and contrast them with those 364 
covered by the target utility-based measure.     365 
The methods used to move from a potentially large set of explanatory variables to a preferred 366 
model that is likely to include a smaller number, and in a particular form, must be detailed. 367 
There are many ways in which such regression models can be determined9.     368 
Model selection and performance 369 
Theoretical justification for the selection of model type(s) should be provided drawing on 370 
previous literature and the specific features of the mapping to be performed, with a particular 371 
focus on the target utility measure. Regression models make assumptions which should be 372 
explicitly acknowledged and tested or assessed for plausibility. The proposed use of the 373 
mapping, if known, should also be discussed. Relevant aspects include the range of disease 374 
for which the results will be used, the manner in which uncertainty is to be considered and 375 
whether the analysis requires only expected utility values conditional on covariates (as is 376 
typically the case in a cohort decision model) or if simulated data is required (as in a trial-377 
based analysis or patient level simulation model).  378 
Results must be reported in a manner that provides transparency: readers of the results must 379 
be made aware of the process of selecting a preferred model(s) from the set of feasible ones 380 
and they must be provided with sufficient information to judge the validity of that process. 381 
This means that they need to be able to fully assess the performance of the preferred model(s) 382 
(and will require details on at least some aspects of performance of the less preferred 383 
models).  Judgements are required at each stage of the model building process: reporting 384 
needs to highlight these judgements and their rationale. Sufficient information should be 385 
supplied to allow readers to be able to use the results of the mapping model in future cost±386 
effectiveness studies. 387 
One aspect of performance that is particularly important is model fit ± the extent to which 388 
modelled values coincide with those observed in the data. Movement to a preferred model 389 
should not mechanistically follow some rule-based on overall fit. Specific judgement will be 390 
required and this will be context specific; for example, whether or not to include a particular 391 
covariate. Detailed information on model fit is required, however, for the final preferred 392 
model(s). Summary measures of fit like the R2 are of very limited value here, particularly 393 
when presented in isolation, and provide little information of the validity of the mapping for 394 
use in subsequent CEA. The degree of between patient variability is inherently high in quality 395 
of life data, given the (warranted) subjective nature of quality of life. This results in relatively 396 
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low R2 statistics. Penalised likelihood statistics, such as the Akaike Information Criteria and 397 
Bayesian Information Criteria (AIC/BIC), provide a more appropriate means for comparisons 398 
of specifications within model types. Other summary measures of fit such as the Mean 399 
Absolute Error (MAE) and Root Mean Squared Error (RMSE) have typically been applied in 400 
the mapping literature. These measures have their origins in the field of forecasting. It should, 401 
therefore, be recognised that these measures can appear very insensitive when applied in the 402 
mapping field because of the limited range of the dependent utility variable and the degree of 403 
variability inherent in patient outcome data. Any measure of model fit should be reported 404 
both for entire sample and for specific data ranges, defined in terms of the clinical 405 
explanatory variable(s). A plot of mean predicted and mean observed utility values 406 
conditional on the clinical variable helps to identify the existence and location of any 407 
systematic bias (see, for example, Wailoo et al.33) and where that bias occurs.  408 
The fit of a model should not be assessed solely by reference to the point estimates of the 409 
predicted values compared to the data. It should also consider the uncertainty around those 410 
predictions and the model outputs once patient variability is included, as described below.    411 
Reporting of results 412 
All coefficient values must be reported to a sufficient number of decimal places to permit 413 
accurate estimation. Rescaling and centering covariates around their sample mean can 414 
facilitate this. Uncertainty in the estimated coefficients and associated correlation is 415 
imperative to allow the reflection of parameter uncertainty in the CEA ± the covariance 416 
matrix should therefore be routinely reported34 to allow probabilistic sensitivity analysis 417 
(PSA) to be undertaken. In addition to parameter uncertainty, the use of a mapping function 418 
to impute data at the individual level (for example, when conducting an analysis alongside a 419 
clinical trial) requires that the individual level variation is also reflected. In real world data, it 420 
is obvious that individuals with identical observable characteristics do not report identical 421 
health utility values. If mapping regression models are used simply to impute the same 422 
conditional expected value for these individuals, that individual level unexplained variability 423 
has been ignored and misrepresents both the clinical study and the results of the mapping. 424 
Information on the assumed degree and form of this variability is contained in the mapping 425 
regression error term(s) distribution and can be used as the basis for simulation methods that 426 
reflect this. Therefore, it is also essential that details of the error terms are reported routinely. 427 
With the availability of on-line materials, published mapping studies have no reason not to 428 
include these important items of information.     429 
The guidance above relating to model selection suggests that one ought not select a model 430 
that is capable of producing estimates that lie outside the feasible range for the utility scale. 431 
But if such a model has been selected then when sampling from the mapping function, either 432 
for uncertainty or variability analysis, the frequency with which these samples lie outside the 433 
feasible range must be reported. It must also be reported how such unfeasible values were 434 
subsequently used or amended in the CEA. When a mapping is produced without any specific 435 
CEA in mind, it can still be useful to report the results of a simulated dataset from the model. 436 
This can help inform future CEAs and also forms a means of comparing the distribution of 437 
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the data simulated from the model to the distribution of the original data (and can thus be 438 
used as part of the model selection process).  439 
Empirical Validation 440 
As with other statistical models, validation of the mapping model is relevant. Much of the 441 
guidance reported here is based on this requirement. The description of the dataset and the 442 
decision problem in which it is to be used, the process of model building and the performance 443 
of the final preferred model ± each of these elements provides information on validation. To 444 
ZKDWH[WHQWFDQZHKDYHFRQILGHQFHWKDWWKHPRGHO¶VSUHGLFWLRQV are accurate within the 445 
relevant patient group and to what extent might they be relevant in other similar patient 446 
groups? Existing UK guidelines on mapping recommend empirical validation14 in this 447 
respect, described as estimation of the model in two datasets, either from two separate studies 448 
(external validation) or from splitting a single dataset (internal validation), though numerous 449 
other methods can be used for internal validation (for example, using bootstrapping-based 450 
approaches). In many situations, these empirical validation techniques will simply not be an 451 
option because there is only one candidate dataset of insufficient sample size to contemplate 452 
splitting.   453 
Where any of these validation methods could feasibly be undertaken, there remains 454 
uncertainty about which of the available range of methods are most appropriate in the 455 
mapping setting and the additional value of the information these analyses provide. Sample 456 
splitting imposes the additional penalty of reduced sample size for estimation. For these 457 
reasons, we believe it would be premature to recommend empirical validation be conducted 458 
for all mapping studies. This is consistent with approaches undertaken for other regression-459 
derived inputs to CEA. 460 
Validation of alternative methodological approaches to the analysis of utility data can be 461 
achieved through repeated head-to-head testing in real-world and simulated datasets from 462 
different disease areas. However, routine multi-sample validation methods are not required 463 
for standard applied mapping studies because of the limitations noted above.  464 
 
 
 
 
 
 
 
 
 15 
 
 465 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. THE USE OF RESULTS FROM MAPPING MODELS. 466 
Selection of a mapping model for a cost-effectiveness study 467 
Analysts may often need to select an existing mapping, perhaps from the published literature, 468 
to populate their cost-effectiveness model. In some situations, there may be no existing 469 
mapping that matches the population of interest. This might be that the precise characteristics 470 
of the patients do not match in terms of demographics, stage or severity of disease. In other 471 
situations it may be a more fundamental disparity such as the mapping being based on 472 
patients with a different disease. For example, the EORTC QLQ30 is a PROM used with 473 
patients with any type of tumour. Mappings have been estimated based on samples of patients 474 
with breast cancer35. Judgements about the suitability of a mapping study in a CEA should be 475 
based on an assessment of the differences between the patients or diseases in question. Are 476 
these differences likely to make the relationship between the mapping covariates and the 477 
target PBM non-generalizable?    478 
 
Summary of reporting standards recommendations 
1. Describe relevant differences between datasets that are candidates for mapping estimation 
2. Give full details of the selected dataset. Describe how the study was run and patients were 
sampled. Provide baseline and follow-XSFKDUDFWHULVWLFVLQFOXGLQJWKHGLVWULEXWLRQRISDWLHQWV¶
disease severity. Missingness in the longitudinal pattern of responses should be described. 
3. Plot the distribution of the utility data.  
4. Justify the type of model(s) selected with reference to the characteristics of the target utility 
distribution and the proposed use of the mapping function. 
5. Compare the dimensions of health covered by the target utility instrument and those covered by 
the explanatory clinical measure(s). 
6. Describe the approach to determining the final model. Include tests conducted and judgements 
made. 
7. Summary measures of fit are of limited value for the total sample. Provide information on fit 
conditional on disease severity as measured by the clinical outcome measure(s). A plot of mean 
predicted versus mean observed utility conditional on the clinical variable(s) should be included. 
8. Coefficient values, error term(s) distributions(s), variances and covariances are required. 
9. Provide an example predicted value for some set of covariates. Consider providing a program that 
calculates predictions for user defined inputs. 
10. Parameter uncertainty in a mapping regression should be reflected using standard methods for 
Probabilistic Sensitivity Analysis (PSA). Assessment of model suitability for use in cost-
effectiveness analysis should also consider the distribution of utility values for PSA, with 
particular focus on whether these lie outside the feasible utility range for the PBM.  
11. When imputing data from a mapping function individual level variability should be incorporated 
using simulation methods and information about the distribution of the error term(s). These 
simulated data can be compared to the raw observed data, including an assessment of the range of 
values compared to the feasible range for the PBM.  
12. Re-estimation of mapping results in a separate dataset is not routinely required. 
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Predicted values  479 
The primary use of mapping for economic evaluation is to predict the mean health state 480 
utility value for a set of explanatory variables: in other words, the expected value conditional 481 
on covariates. If the guidance presented here has been followed, then a full understanding of 482 
the model specification and the estimated coefficients will have been provided and it will be 483 
obvious how to derive the required expected values. It may also be helpful for the mapping 484 
study to report the expected utility value and standard error for a given set of covariates for 485 
future reference. Some published studies go further and provide pre-programmed spreadsheet 486 
calculators as supplementary files25,33.  487 
Variability 488 
A full specification of the statistical model and its estimated results, including error term(s) 489 
distribution(s), provides the required information to allow an analyst to reflect individual 490 
level variability. At its simplest, this may comprise a single normally distributed error term 491 
with mean zero and variance as reported. It is, therefore, straightforward to sample from the 492 
relevant conditional distribution to reflect variability around any required health state/patient 493 
characteristics. 494 
Uncertainty 495 
PSA is the standard accepted method for reflecting parameter uncertainty in health economic 496 
models. Monte Carlo simulation can be used to sample from the relevant joint distribution for 497 
regression model inputs, including mapping studies, provided the model specification, 498 
coefficient estimates and variance-covariances are reported.  499 
 
7. CONCLUSIONS   500 
Whilst the inclusion of appropriate preference-based measures in clinical studies is always 501 
recommended (see ISPOR Good Practice Guide Wolowacz et al10 for guidance on this issue), 502 
this will not always be feasible or sufficient for the needs of economic evaluation. Mapping 503 
is, therefore, needed to allow analysts to bridge the gap between clinical evidence and the 504 
evidence required for economic evaluation. Provided that mapping analyses are undertaken 505 
appropriately, reported transparently and their results used appropriately, decision makers can 506 
be confident in the validity of estimates obtained in this manner.    507 
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